Cardiol Therapeutics Inc (TSX:CRDL)
C$ 3.6 -0.21 (-5.51%) Market Cap: 248.39 Mil Enterprise Value: 219.99 Mil PE Ratio: 0 PB Ratio: 12.96 GF Score: 33/100

Cardiol Therapeutics Inc at Emerging Growth Conference Transcript

May 25, 2022 / NTS GMT
Release Date Price: C$1.47 (+7.30%)
Ana Berry
EmergingGrowth.com - Moderator

Welcome, everybody. Good morning, good evening, good afternoon, wherever this is finding you, I hope you're well. Welcome to the 31st Emerging Growth Conference. I'm Ana Berry. I'll be your host today. So as always, we have an exciting list of companies in a wide range of growth sectors presenting to you today.

(Conference Instructions)

Today, we have nine companies presenting. So, without further ado, I will introduce our first, please welcome Cardiol Therapeutics Inc. It trades on the Nasdaq under the symbol, CRDL and on the TSX under the symbol, CRDL. And is a clinical-stage life sciences company focused on the research and clinical development of cannabinoid and an antifibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease. Please welcome its CEO, David Elsley.

Welcome, David. How are you doing today?

David Elsley
Cardiol Therapeutics Inc. - President and CEO

I'm doing great. Thanks very much for having us here today. It's a great -- very thrilled to have the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot